Treatment of CD30‐Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases

摘要

Background.Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, and patients with CD30‐expressing embryonal carcinomas have worse progression‐free survival and overall survival than those with CD30‐negative tumors. The objective of this study () was to characterize the antitumor activity of brentuximab vedotin in patients with CD30‐expressing nonlymphomatous malignancies. Enrolled patients included seven patients with relapsed or refractory germ cell tumors or metastatic sex cord stromal tumors described in this case series.